---
title: 'Amitriptyline use in individuals with KCNQ2/3 gain-of-function variants: A
  retrospective cohort study'
date: '2025-02-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39962862/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250218170842&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'OBJECTIVE: Heterozygous gain-of-function (GOF) variants in KCNQ2 and
  KCNQ3, encoding the voltage-gated potassium channel subunits Kv7.2 and Kv7.3, lead
  to neurodevelopmental disorders for which no established treatments are available.
  Amitriptyline, an antidepressant, blocks Kv7.2/Kv7.3 and has previously been reported
  to be effective in a single individual with a KCNQ2 GOF variant. We designed a retrospective,
  single-arm, multicenter study to investigate the effects of amitriptyline in ...'
disable_comments: true
---
OBJECTIVE: Heterozygous gain-of-function (GOF) variants in KCNQ2 and KCNQ3, encoding the voltage-gated potassium channel subunits Kv7.2 and Kv7.3, lead to neurodevelopmental disorders for which no established treatments are available. Amitriptyline, an antidepressant, blocks Kv7.2/Kv7.3 and has previously been reported to be effective in a single individual with a KCNQ2 GOF variant. We designed a retrospective, single-arm, multicenter study to investigate the effects of amitriptyline in ...